As pharma leverages real-world uses of AI, the industry has also been careful about big-picture hype for the technology as some of its limitations become clear.
Learn more.
A curious email landed in my inbox this week. HHS announced it’s publishing the actions of the Make America Healthy Again agenda via a new tracker. But I was struck by the question: Where is the MAHA report?
In May, the agency released an initial report examining the root causes of childhood chronic diseases. But a second report from the MAHA commission that would outline the policy reform priorities of the administration was due Aug. 12 and never arrived. According to the White House, publication of the report is delayed, but a leaked draft made the media rounds this week, potentially revealing what could be inside.
Fortunately for pharma companies, the draft spells good news about the potential upheaval of direct-to-consumer advertising rules. While some health leaders have pushed for a ban on DTC ads, the leaked draft contains much softer proposals to increase oversight. Today, we’re tracking what’s in the report and which DTC advertising reforms are still in play.
The story of the rare disease market in recent years has been centered around growth with large pharmas starting to see more promise in the space as deals tick up. Learn more in this Trendline.
The rundown from yesterday
Yesterday, we explored how the advances in cryobiology are improving cell therapy access and cost.
PharmaVoice readers who said their pharma company is considering new investments in U.S. manufacturing. Just 19% said new investments were off the table.
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
